MA56038B1 - Inhibiteurs à petite molécule de kinase induisant nf-kb - Google Patents

Inhibiteurs à petite molécule de kinase induisant nf-kb

Info

Publication number
MA56038B1
MA56038B1 MA56038A MA56038A MA56038B1 MA 56038 B1 MA56038 B1 MA 56038B1 MA 56038 A MA56038 A MA 56038A MA 56038 A MA56038 A MA 56038A MA 56038 B1 MA56038 B1 MA 56038B1
Authority
MA
Morocco
Prior art keywords
disorders
small molecule
compounds
molecule inhibitors
inducing kinase
Prior art date
Application number
MA56038A
Other languages
English (en)
Other versions
MA56038A (fr
Inventor
Alec D. Lebsack
Kevin D. Kreutter
Wenying Chai
Paul J. KRAWCZUK
J. Kent Barbay
Wendy Eccles
Michael D. Hack
Aaron T. HERRMANN
William M. Jones
Daniel J. Pippel
Alexander R. ROVIRA
Ronald L. Wolin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA56038A publication Critical patent/MA56038A/fr
Publication of MA56038B1 publication Critical patent/MA56038B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés agissant en tant qu'inhibiteurs de NIK, des compositions pharmaceutiques comprenant de tels composés, et des procédés d'utilisation de ces derniers. Ces composés et compositions pharmaceutiques sont destinés pour être utilisés dans la prévention ou le traitement de maladies telles que le cancer (notamment des malignités à lymphocytes B, y compris les leucémies, les lymphomes et le myélome), des troubles inflammatoires, des troubles auto-immuns, des troubles immunodermatologiques tels que la pustulose palmoplantaire et la hidradenite suppurativa, ainsi que des troubles métaboliques tels que l'obésité et le diabète.
MA56038A 2019-05-31 2020-05-29 Inhibiteurs à petite molécule de kinase induisant nf-kb MA56038B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US201962907833P 2019-09-30 2019-09-30
EP20733688.4A EP3976597B1 (fr) 2019-05-31 2020-05-29 Inhibiteurs à petite molécule de kinase induisant nf-kb
PCT/EP2020/065024 WO2020239999A1 (fr) 2019-05-31 2020-05-29 Inhibiteurs à petite molécule de kinase induisant nf-kb

Publications (2)

Publication Number Publication Date
MA56038A MA56038A (fr) 2022-04-06
MA56038B1 true MA56038B1 (fr) 2024-11-29

Family

ID=71108552

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56038A MA56038B1 (fr) 2019-05-31 2020-05-29 Inhibiteurs à petite molécule de kinase induisant nf-kb

Country Status (37)

Country Link
US (3) US11254673B2 (fr)
EP (2) EP3976597B1 (fr)
JP (2) JP7547387B2 (fr)
KR (1) KR20220027871A (fr)
CN (2) CN114222737B (fr)
AU (1) AU2020282005B2 (fr)
BR (1) BR112021023796A2 (fr)
CL (1) CL2021003142A1 (fr)
CO (1) CO2021017838A2 (fr)
CR (1) CR20210587A (fr)
DK (1) DK3976597T3 (fr)
DO (1) DOP2021000244A (fr)
EC (1) ECSP21093623A (fr)
ES (1) ES2989387T3 (fr)
FI (1) FI3976597T3 (fr)
HR (1) HRP20241352T1 (fr)
HU (1) HUE068694T2 (fr)
IL (1) IL288387B2 (fr)
JO (1) JOP20210318B1 (fr)
LT (1) LT3976597T (fr)
MA (1) MA56038B1 (fr)
MD (1) MD3976597T2 (fr)
MX (1) MX2021014679A (fr)
MY (1) MY205653A (fr)
PE (1) PE20220768A1 (fr)
PH (1) PH12021553011A1 (fr)
PL (1) PL3976597T3 (fr)
PT (1) PT3976597T (fr)
RS (1) RS66105B1 (fr)
SA (1) SA521430960B1 (fr)
SG (1) SG11202112994WA (fr)
SI (1) SI3976597T1 (fr)
SM (1) SMT202400418T1 (fr)
TW (2) TWI850390B (fr)
UA (1) UA130430C2 (fr)
UY (1) UY38721A (fr)
WO (1) WO2020239999A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274082B2 (en) 2019-05-31 2022-03-15 Ikena Oncology, Inc. Tead inhibitors and uses thereof
ES2989387T3 (es) * 2019-05-31 2024-11-26 Janssen Pharmaceutica Nv Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb
WO2020243423A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
WO2023217879A1 (fr) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Dérivés de pyrrolidione utiles comme inhibiteurs de la kinase d'induction de nf-kb
AU2023267946A1 (en) * 2022-05-11 2025-01-02 Janssen Pharmaceutica Nv Pyrrolidinone derivatives as inhibitors of nf kappa b inducing kinase
KR20250133319A (ko) 2022-12-22 2025-09-05 베링거 인겔하임 인터내셔날 게엠베하 Her2 억제제의 결정형
WO2025020886A1 (fr) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 Dérivé cyclique d'azaquinazoline et son utilisation
KR20260059568A (ko) 2023-07-28 2026-04-30 베링거 인겔하임 인터내셔날 게엠베하 Her2 억제제의 제조 방법
WO2025235874A1 (fr) * 2024-05-10 2025-11-13 Schrödinger, Inc. Hétérocycles utiliséés en tant qu'inhibiteurs d'egfr
WO2026029041A1 (fr) * 2024-07-30 2026-02-05 日本たばこ産業株式会社 Composé pyrazolopyrimidine et son utilisation pharmaceutique

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
HRP20090495T1 (hr) 2004-04-02 2009-10-31 Osi Pharmaceuticals Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom
AU2005271737A1 (en) * 2004-08-03 2006-02-16 Wyeth Indazoles useful in treating cardiovascular diseases
TW200628159A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
KR101227228B1 (ko) 2004-11-12 2013-01-28 스태츠 칩팩, 엘티디. 와이어 본드 배선
US20110086834A1 (en) 2008-06-26 2011-04-14 Amgen Inc. Alkynyl alcohols as kinase inhibitors
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
KR20130133051A (ko) * 2011-03-16 2013-12-05 에프. 호프만-라 로슈 아게 6,5-헤테로사이클릭 프로파길릭 알콜 화합물 및 이의 용도
KR20140131359A (ko) 2012-02-17 2014-11-12 에프. 호프만-라 로슈 아게 트라이사이클릭 화합물 및 이의 사용 방법
US9159402B2 (en) 2012-07-02 2015-10-13 Stmicroelectronics International N.V. SRAM bitcell implemented in double gate technology
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
JP2015536981A (ja) 2012-11-05 2015-12-24 ザフゲン，インコーポレイテッド 三環式化合物ならびにその製造および使用方法
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
MX2016002241A (es) * 2013-08-22 2016-05-31 Hoffmann La Roche Alcoholes de alquinilo y metodos de uso.
CN105658640A (zh) * 2013-08-22 2016-06-08 豪夫迈·罗氏有限公司 炔基醇和应用方法
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
CN119591582A (zh) 2014-04-14 2025-03-11 阿尔维纳斯运营股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法
MX371151B (es) 2014-10-23 2020-01-20 Janssen Pharmaceutica Nv NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
US9981962B2 (en) 2014-10-23 2018-05-29 Janssen Pharmaceutica Nv Pyrazole derivatives as NIK inhibitors
ES2718557T3 (es) 2014-10-23 2019-07-02 Janssen Pharmaceutica Nv Nuevos compuestos como inhibidores de nik
BR112017007704B1 (pt) 2014-10-23 2023-04-11 Janssen Pharmaceutica N.V Derivados de pirazolopirimidina como inibidores de nik, seu uso e composição farmacêutica que os compreende
JP2018510140A (ja) 2015-02-25 2018-04-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルキニルアルコール及び使用方法
US11001569B2 (en) 2016-01-22 2021-05-11 Janssen Pharmaceutica Nv 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
HUE047684T2 (hu) 2016-01-22 2020-05-28 Janssen Pharmaceutica Nv Új szubsztituált cianoindolin származékok mint NIK inhibitorok
WO2018002219A1 (fr) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Nouveaux dérivés de cyanoindoline comme inhibiteurs de nik
KR102517352B1 (ko) 2016-06-30 2023-03-31 잔센파마슈티카엔.브이. Nik 억제제로서의 헤테로방향족 유도체
CN109641894B (zh) 2016-08-24 2022-09-09 豪夫迈·罗氏有限公司 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法
EP3504192B1 (fr) 2016-08-24 2022-04-06 F. Hoffmann-La Roche AG Dérivés de 2-azabicyclo [3.1.0]hexan-3-one et procédés d'utilisation
EP3649127B1 (fr) 2017-07-06 2021-09-08 Janssen Pharmaceutica NV Dérivés d'azaindoline substitués en tant qu'inhibiteurs de nik
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途
BR112021021738A2 (pt) 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
US11274082B2 (en) 2019-05-31 2022-03-15 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN114206900A (zh) 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物
WO2020243423A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
ES2989387T3 (es) * 2019-05-31 2024-11-26 Janssen Pharmaceutica Nv Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
AU2023267294A1 (en) 2022-05-11 2025-01-02 Janssen Pharmaceutica Nv PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE

Also Published As

Publication number Publication date
ECSP21093623A (es) 2022-01-31
US20230080834A1 (en) 2023-03-16
ES2989387T3 (es) 2024-11-26
MA56038A (fr) 2022-04-06
DOP2021000244A (es) 2022-04-18
JP2024167319A (ja) 2024-12-03
US11827634B2 (en) 2023-11-28
US20210300918A1 (en) 2021-09-30
UY38721A (es) 2020-11-30
HRP20241352T1 (hr) 2024-12-20
US11254673B2 (en) 2022-02-22
JP7547387B2 (ja) 2024-09-09
MX2021014679A (es) 2022-04-06
HUE068694T2 (hu) 2025-01-28
CL2021003142A1 (es) 2022-08-19
TW202517638A (zh) 2025-05-01
TW202110842A (zh) 2021-03-16
PL3976597T3 (pl) 2024-12-16
CN114222737B (zh) 2024-07-26
SI3976597T1 (sl) 2024-11-29
EP4467199A2 (fr) 2024-11-27
WO2020239999A1 (fr) 2020-12-03
PE20220768A1 (es) 2022-05-16
IL288387A (en) 2022-01-01
CA3143350A1 (fr) 2020-12-03
MD3976597T2 (ro) 2025-01-31
JP2022534302A (ja) 2022-07-28
TWI850390B (zh) 2024-08-01
EP3976597A1 (fr) 2022-04-06
SA521430960B1 (ar) 2024-11-12
MY205653A (en) 2024-11-02
TWI906955B (zh) 2025-12-01
PT3976597T (pt) 2024-10-22
JOP20210318B1 (ar) 2025-10-01
EP3976597B1 (fr) 2024-08-28
US20240199605A1 (en) 2024-06-20
US12617789B2 (en) 2026-05-05
JOP20210318A1 (ar) 2023-01-30
EP4467199A3 (fr) 2025-03-05
AU2020282005B2 (en) 2026-02-12
CR20210587A (es) 2022-02-11
CN114222737A (zh) 2022-03-22
LT3976597T (lt) 2024-10-10
SG11202112994WA (en) 2021-12-30
BR112021023796A2 (pt) 2022-02-08
IL288387B2 (en) 2026-01-01
DK3976597T3 (da) 2024-09-09
PH12021553011A1 (en) 2022-11-07
FI3976597T3 (fi) 2024-09-25
CN118908957A (zh) 2024-11-08
AU2020282005A1 (en) 2021-12-23
UA130430C2 (uk) 2026-02-18
RS66105B1 (sr) 2024-11-29
IL288387B1 (en) 2025-09-01
CO2021017838A2 (es) 2022-01-17
KR20220027871A (ko) 2022-03-08
SMT202400418T1 (it) 2024-11-15

Similar Documents

Publication Publication Date Title
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
MA30999B1 (fr) Composés.
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
EP4467199A3 (fr) Inhibiteurs à petites molécules de kinase induisant nf-kb
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
MA49673B1 (fr) Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA34474B1 (fr) Agonistes de gpr40
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
MA38688B1 (fr) Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
WO2018224736A3 (fr) Dérivés stéroïdiens thérapeutiquement actifs
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine